Stone House Investment Management’s Definium Therapeutics DFTX Stock Holding History

Stone House Investment Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47K	Hold	1,000	–	–	0.01%	228
2026 Q1	$18.9K	Hold	1,000	–	–	﹤0.01%	278
2025 Q4	$13.4K	Hold	1,000	–	–	﹤0.01%	294
2025 Q3	$11.8K	Hold	1,000	–	–	﹤0.01%	271
2025 Q2	$6.49K	Hold	1,000	–	–	﹤0.01%	296
2025 Q1	$5.85K	Buy	+1,000	New	+$7.16K	﹤0.01%	298

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Stone House Investment Management's DFTX Position: Q2 2026 in Review

Stone House Investment Management held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 1,000 shares worth $47K. The position accounts for 0.01% of the portfolio, ranked #228.

Stone House Investment Management first reported a position in DFTX in Q1 2025 and has held it in 6 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Stone House Investment Management held 1,000 shares of Definium Therapeutics worth $47K as of Q2 2026.
Stone House Investment Management left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up 0.01% of Stone House Investment Management's portfolio in Q2 2026, its #228 holding.
Stone House Investment Management first reported a position in Definium Therapeutics in Q1 2025 and has held it in 6 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.